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Abstract: With the rapid progress of genetic engineering and gene therapy, the World Anti-Doping
Agency has been alerted to gene doping and prohibited its use in sports. However, there is no
standard method available yet for the detection of transgenes delivered by recombinant adenoviral
(rAdV) vectors. Here, we aim to develop a detection method for transgenes delivered by rAdV
vectors in a mouse model that mimics gene doping. These rAdV vectors containing the mCherry gene
was delivered in mice through intravenous injection or local muscular injection. After five days, stool
and whole blood samples were collected, and total DNA was extracted. As additional experiments,
whole blood was also collected from the mouse tail tip until 15 days from injection of the rAdv
vector. Transgene fragments from different DNA samples were analyzed using semi-quantitative
PCR (sqPCR), quantitative PCR (qPCR), and droplet digital PCR (ddPCR). In the results, transgene
fragments could be directly detected from blood cell fraction DNA, plasma cell-free DNA, and stool
DNA by qPCR and ddPCR, depending on specimen type and injection methods. We observed that a
combination of blood cell fraction DNA and ddPCR was more sensitive than other combinations used
in this model. These results could accelerate the development of detection methods for gene doping.
Keywords: gene doping; gene therapy; droplet digital PCR; adenoviral vector
Genes 2019, 10, 436; doi:10.3390/genes10060436 www.mdpi.com/journal/genes
Genes 2019, 10, 436 2 of 13
1. Introduction
Doping is an act of raising competitive abilities to achieve success by using substances or methods
prohibited in sports [1]. Doping in sports, especially in festivals such as the Olympic Games and in
world or local championships for various competitions, is considered illegal and against the spirit of
the game. The World Anti-Doping Agency (WADA) was established in 1999, and has been involved
in scientific research on doping, anti-doping education, development of anti-doping strategies, and
monitoring of the World Anti-Doping Code (hereafter the Code) [2] to ensure soundness and fairness
in sports worldwide.
With the rapid progress of genetic engineering technology and gene therapy, WADA has been
strongly alerted against gene doping. Since its early days, WADA has added “gene doping” to its
prohibited list. Subsequently, in 2004, WADA created a panel of experts on gene doping to investigate
the latest advances in the field of gene therapy, and the methods for detecting doping [3]. In January
2018, WADA extended the ban on gene doping to include all forms of gene editing. Therefore, the list
of prohibited substances currently includes “gene editing agents designed to alter genome sequences
and/or the transcriptional or epigenetic regulation of gene expression” [4]. However, there are no
established standard methods for detecting or preventing gene doping to date.
In recent years, genetic engineering technology has rapidly advanced, resulting in the progression
of gene therapy. In gene therapy, various viral vectors have been frequently devised and applied. Vectors
based on recombinant adeno-associated viruses (rAAV) and recombinant adenoviruses (rAdV) have
been widely used in clinical trials and animal experiments for investigating gene therapy. For example,
rAAV vectors have been applied in the treatment of diseases, such as Duchenne muscular dystrophy
(DMD) [5], hemophilia B [6,7], and Leber congenital amaurosis (LCA) [8,9], during clinical trials or
animal experiments as a form of gene therapy. Moreover, rAdV vectors also have been applied in gene
therapy for the treatment of certain human cancers [10–12]. In China, two rAdV vector-based gene
therapy products, namely Gendicine (Shenzhen SiBiono GeneTech Co., Ltd., Shenzhen, China) [12,13]
and Oncorine (Sunway Biotech Co., Ltd., Taipei, Taiwan), were approved for clinical use in humans
to treat head and neck cancer, and were released into the commercial market in 2003 and 2006,
respectively [14]. Additionally, rAdV vectors were the most commonly used vectors in approved
clinical trials of gene therapy (541 cases, 18% of the total) worldwide until December 2018 [15] (Table 1).
It can be assumed that gene doping methods may employ clinical trial methods. Therefore, there is a
possibility that rAAV or rAdV vectors, especially rAdV vectors, can be used as gene doping agents
to enhance athletic performance by artificially modifying gene expression in specific human organs.
In this study, we focused on rAdV vectors, since rAdV vectors are the most commonly used in clinical
trials [15] (Table 1), and are also used as prescription drugs [12–14].
Table 1. Types and relative numbers of the top seven clinically approved vectors used in gene therapy.
Vector
Gene Therapy Clinical Trials
Number %
Adenovirus 541 18.5
Retrovirus 514 17.5
Naked/Plasmid DNA 452 15.4
Lentivirus 278 9.5
Adeno-associated virus 238 8.1
Vaccinia virus 133 4.5
Lipofection 119 4.1
Others 774 26.4
Total 2930 100
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The data in Table 1 were obtained from the website of Gene Therapy Clinical Trials Worldwide [15].
The top seven vectors include five viral vectors, with rAdV vectors being the most commonly used.
It is believed that these viral vectors can be used for transgene delivery in gene doping.
2. Materials and Methods
2.1. Cloning of Recombinant Adenoviral Vectors Containing the mCherry Gene
The following plasmids were used in this study: plasmid pcDNA3.1–Peredox–mCherry was a gift
from Gary Yellen [16] (Addgene plasmid #32383; http://n2t.net/addgene:32383; RRID: Addgene_32383);
pENTR4 (Thermo Fisher Scientific, Waltham, MA, USA); and pAd/CMV/V5-DEST (Thermo Fisher
Scientific). HEK 293A cells (Thermo Fisher Scientific) were used to clone and amplify recombinant
adenoviral (rAdV) vectors. The mCherry gene, having restriction enzyme sites of 5′-EcoRI and 3′-NotI,
was amplified by PCR with templated pcDNA3.1–Peredox–mCherry. It was then cloned into a pENTR4
plasmid between EcoRI and NotI sites by restriction enzyme digestion, followed by ligation with
T4 ligase (Promega, Madison, WI, USA). The sequences of inserted mCherry genes in the pENTR4
plasmids were read using sanger sequencing and confirmed to be correct sequences. Using Gateway LR
Clonase Enzyme mix (Thermo Fisher Scientific), and according to the manufacturer protocol, pENTR4
containing the mCherry gene was allowed to react and recombine with pAd/CMV/V5-DEST (destination
vector) in an LR reaction to move the mCherry gene into a pAd/CMV/V5-DEST plasmid, which can make
rAdV type 5, containing the transgene. Subsequently, a pAd/CMV/V5-DEST plasmid containing the
mCherry gene was digested with Pac I restriction enzymes (New England Biolabs, Ipswich, MA, USA),
and the resulting liner plasmids were transfected using Lipofectamine LTX Reagent (Thermo Fisher
Scientific) into HEK 293A cells cultured in Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher
Scientific), containing 10% Fetal Clone III (GE Healthcare, Chicago, IL, USA) and antibiotics (Nacalai
tesque, Kyoto, Japan) to synthesize and amplify rAdV vectors containing the mCherry gene. Amplified
rAdV vectors were purified by CsCl density gradient ultracentrifugation followed by gel filtration,
according to the protocol described by Takeuchi et al. [17,18]. The concentration of rAdV viral particles
(VP) was measured on a spectrophotometer, according to the method of Sweeney and Hennessey [19].
To confirm the expression of a functional mCherry protein, HEK 293A cells were seeded at a density of
2.5 × 105 cells per well in six-well plates, and were cultured in DMEM containing 10% Fetal Clone III
and antibiotics. After 24 h, the cells were infected with rAdV vectors (2.8 × 109 VP/mL of medium) to
allow the expression of mCherry. After 24 h of induction, the red fluorescence of mCherry was analyzed
using fluorescence microscope.
2.2. Animal Experiments
Animal experiments in this study were approved by the Animal Care Committee, University
of Tsukuba (approval numbers: 18–118 and 18–474). The overview of the experiments is shown
in Figure 1. Six-week-old IC57BL/6 male mice were purchased from the Central Laboratories for
Experimental Animals (CLEA, Tokyo, Japan). The mice were allowed to grow until they reached
10 weeks old, with an average body weight of 26.1 g (SD = ±1.8 g). At this point, they were sacrificed
for further experiments.
2.2.1. Acute Experiments
The rAdV vectors containing the mCherry gene (2.1× 1011 VP) were injected into left orbital veins
(intravenous; IV group, n = 7) or local muscle (LM group, n = 7) of both the tibialis anterior (TA)
muscles of mice under general anesthesia by inhalation agent isoflurane. When rAdV vectors were
used intravenously (IV), most of the rAdV transgenes accumulated in the liver. Control mice were
left untreated (Con. Group, n = 6). After five days of injection, mice were placed in an empty cage
and were allowed to defecate. Stool samples were quickly collected into microtubes and placed on ice.
After collecting stool samples from experimental mice, whole blood was extracted from the inferior
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vena cava using ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. During this procedure,
mice were given general anesthesia by inhalation agent isoflurane. After blood collection, the mice
were euthanized. Whole blood was then centrifuged and separated into plasma and blood cell fraction.
Liver and TA muscle were also harvested to check gene and protein expression after infection with
rAdV vectors. Collected stool samples, plasma samples, and blood cell fractions were stored at −20 ◦C,
whereas liver and TA muscle samples were stored at −80 ◦C till further analysis.Genes 2019, 10, x FOR PEER REVIEW 4 of 14 
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2.2.2. Chronic Experiments
Initially, as pre-samples, 50–100 µL of whole blood was collected from mice tail tip cuttings of
2–3 mm, under general anesthesia by isoflurane. Then, mice were injected with rAdV vectors of the
same amounts and by same method as those described in Section 2.2.1. After 24 h of injection, whole
blood was again collected for the next 15 days, a total of eight times on every other day by the same
ethods. The ollect d whole blood was stored at −20 ◦C until further analysis.
2.3. Confirmation of Gene and Protein Expression by Infection of rAdV Vectors In Vivo
For acute experiments, the total RNA and proteins were extracted from isolated liver and TA muscle
tissues as follows. Sepasol-RNA I Super G (Nacalai Tesque, Kyoto, Japan) was used for total RNA
extraction, according to the manufacturer’s instructions. Using 500 ng of total RNA and PrimeScrip RT
Master Mix (Takara Bio, Shiga, Japan), reverse transcription was carried out to synthesize cDNA. The
cDNA synthesized was diluted 10-fold using nuclease-free water. Subsequently, quantitative PCR
(qPCR) was performed to confirm mCherry expression in different tissues with duplicate measurements,
using a KAPA SYBR Fast qPCR kit (NIPPON Genetics, Tokyo, Japan) for 18S ribosomal RNA and
PrimeTime Gene Expression Master Mix (Integrated DNA Technologies) for mCherry, normalized to 18S
ribosomal RNA expression with delta CT calculations. Primer sequences are given in Table 2. To extract
the total protein, the tissues were homogenized in a lysis buffer (0 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1% NP40, 1 mM EDTA) with an added pr tease inhibitor cocktail (Nacalai Tesqu ), and subjected to
Western blotting using 10 µg protein sample. Aft r the protein transfer, the membrane was incubated in
TBS-T buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20) containing 5% Bovine Serum Albumin
(BSA) for blocki g, and subsequently in anti-mCherry antibody (PM005; MBL) vernight at 4 ◦C with
gentle shaking. The next day, after thorough washes, the membrane was incubated with a secondary
antibody conjugated with horseradish peroxidase for 1 h with gentle shaking. Finally, the protein
bands of mCherry were visualized with ECL Select W s ern blotting De ection Reagent (GE Healthcare)
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using LAS-4000 software (GE Healthcare). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as a loading control (C65); (Santa Cruz Biotechnology, Sant Cruz, CA, USA).
Table 2. Primer sequences used in this study.
Methods Targets Sequences Predicted Size (bp)
sqPCR mCherry gene body Forward CACGAGTTCGAGATCGAGGG 234Reverse GCCGTCCTCGAAGTTCATCA
sqPCR CMV promoter Forward CACGCCCATTGATGTACTGC 247Reverse ACGCCAATAGGGACTTTCCA
qPCR, ddPCR: Taq
man probe assay
mCherry gene body
Forward GGCACCAACTTCCCCTCC
115Probe 56FAM/CATGGTCTT/ZEN/CTTCTGCAT/3IABkFQ
Reverse TCTGCTTGATCTCGCCCTTC
qPCR: SYBR green
assay 18s rRNA
Forward AGTCCCTGCCCTTTGTACACA
70Reverse CGATCCGAGGGCCTCACTA
2.4. DNA Extraction and Detection of Transgenes Using Three Different PCR Methods
For acute experiments, total DNA was extracted from collected stool, plasma, and blood cell
fractions. A NucleoSpin Plasma XS (Takara Bio, Kusastu, Japan) kit was used to isolate plasma cell-free
DNA (cfDNA) from 240 µL of plasma. A NucleoSpin Blood (Takara Bio) kit was used to isolate DNA
from 200 µL of blood cell fraction. A phenol/chloroform/isoamyl alcohol solution (Nacalai Tesque)
was used to isolate DNA from the stool of one piece. The concentration of total extracted DNA was
measured, and the final concentration was adjusted to 50 ng/µL for stool- and blood cell fraction DNA.
Since plasma cfDNA had a very low concentration, it was used as an undiluted solution. For chronic
experiments, the total DNA was extracted from 50–100 µL of whole blood using NucleoSpin Blood,
and its final concentration was adjusted to 50 ng/µL.
Using DNA samples of acute experiments, semi-quantitative PCR (sqPCR), real-time quantitative
PCR (qPCR), and droplet-digital PCR (ddPCR) were performed to detect transgene fragments. For
DNA samples of chronic experiments, only ddPCR was performed. All primer sequences used in these
PCR methods are given in Table 2.
2.5. Semi-Quantitative PCR (sqPCR)
Kod Plus (TOYOBO, Osaka, Japan) reagent was used to perform sqPCR. The template volume
and primer concentrations were 1 µL and 300 nM, respectively, for a total reaction volume of 10 µL
per sample. The conditions maintained in the thermal cycler were 94 ◦C for 2 min; 98 ◦C for 10 s,
60 ◦C for 30 s and 68 ◦C for 30 s, for 35 cycles; and then 4 ◦C for infinite hold. The amplicons were
subjected to electrophoresis and visualized using ethidium bromide in an LAS-4000 transilluminator
(GE Healthcare).
2.6. Real-Time Quantitative PCR (qPCR)
PrimeTime Gene Expression Master Mix (Integrated DNA Technologies, Coralville, IA, USA)
reagent was used to perform qPCR. The template volume, primer, and probe concentrations
were 2 µL, 500 nM, and 250 nM, respectively, for a total reaction volume of 10 µL per sample.
The pcDNA3.1–Peredox–mCherry plasmids (10 pg/µL) were used as standard DNA to perform absolute
quantification. The conditions maintained in the thermal cycler were 95 ◦C for 3 min; and 95 ◦C for
3 s and 60 ◦C for 30 s, for 35 cycles. Melting curve was analyzed on QuantStudio 5 Real-Time PCR
Systems (Thermo Fisher Scientific). All samples were measured in duplicate, and the coefficient of
determination (R2) of the standard curve was equal to 0.98.
2.7. Droplet Digital PCR (ddPCR)
To form droplets, ddPCR Supermix for Probes and Droplet Generator oil (Bio Rad, Hercules, CA,
USA) were used. The template volume, primer, and probe concentration were 1 µL, 500 nM, and
250 nM, respectively, for a total reaction volume of 20 µL per sample. Droplets were formed by an
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automated droplet generator (Bio Rad). The conditions maintained in the thermal cycler were 95 ◦C
for 10 min; 94 ◦C for 30 s and 60 ◦C for 1 min, for 40 cycles; 4 ◦C for 5 min; 90 ◦C for 5 min; and 4 ◦C
-infinite hold. The droplets were analyzed as PCR-positive or PCR-negative by QX200 Droplet Digital
PCR System (Bio Rad). DNA samples from chronic experiments were also subjected to ddPCR using a
similar method. All samples were measured in duplicate.
2.8. Statistics
The bar graph shows average ± SD and plots of individual values. The tables show individual
absolute values and the median. The bar graph and table data were subjected to a Kruskal–Wallis
H test (one-way ANOVA of ranks), followed by a two-stage Benjamini, Krieger, and Yekutieli False
Discovery Rate (FDR) procedure as a post-hoc test, using GraphPad Prism version 7.04. A p value less
than 0.05 was considered to be statistically significant.
3. Results
3.1. The mCherry Gene and Protein Were Sufficiently Expressed Both In Vitro and In Vivo
The red fluorescent signal of mCherry protein after infection with rAdV vectors was confirmed in
HEK 293A cells (Figure 2A). In acute experiments, RNA and protein expression of mCherry were also
confirmed in the liver and TA muscle in mice infected with rAdV (Figure 2B,C).
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Figure 2. Confirmed gene and protein expression by the recombinant adenoviral (rAdV) vector. RNA 
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Figure 2. Confirmed gene and protein expression by the recombinant adenoviral (rAdV) vector. RNA
and functional proteins were sufficientl e ressed both in vitro and in vivo. (A) Fu ctional protein
expr ssion of mCherry in HEK 293A cells. (B) Gene expression f mCherry in the liver o tibialis anterior
(TA) muscle, detected by qPCR. (C) Protein expression of mCherry in the liver or TA muscle, shown
by Western blotting of representative samples. IV means intravenous injection, and LM means local
muscular injection of the rAdV vectors in the TA muscle. **: p < 0.01, ***: p < 0.001.
3.2. The Three PCR Methods Showed Each Characteristic and Could Detect Transgene Fragments in
Acute Experiments
In sqPCR, transgene fragments were detected with strong signals for blood cell fraction DNA, as
well as very weak signals for other DNA samples that could not be clearly distinguished into positive
or negative signals (Figure 3).
In the qPCR, using the TaqMan probe, transgene fragments were detected in all specimens in the
IV group, with strong signals from the blood cell fraction DNA. However, small amounts of transgene
fragments were observed in the blood cell fraction DNA, while no fragments were detected in the
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plasma and stool DNA of the LM group. Additionally, variations between individual values were very
large (Table 3).
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Figure 3. Detection of transgene fragments in representative samples using semi-quantitative PCR
(sqPCR). Blood cell fraction DNA samples show strong signals, but other samples show very weak
signals. IV means intravenous injection, and LM means local muscular injection of the rAdV vectors in
the tibialis anterior (TA) muscle. PC. 1: positive control of rAdV DNA containing the mCherry gene
(10 pg/µL). PC. 2: positive control of liver DNA containing the mCherry gene with a rAdV induction
(10 ng/µL). NC. 1: negative control of mouse DNA (50 ng/µL). NC. 2: Distilled water (DW) as a
negative control.
Table 3. Detection of transgene fragments from qPCR. A high number of transgene fragments was
detected in the blood cell fraction DNA in the IV group. IV means i travenous injection, and LM means
local m scular injection of the rAdV in the tibialis ant rior (TA) muscle. a: p < 0.01 vs. control (c n.)
within s me specim ns. : p < 0.05 vs. local injection w thin same specimens. c: p < 0.05 vs. con.
within same specimens.
Group Mouse No.
Copy/µL of Transgene
Blood Cell Fraction-DNA Plasma-cfDNA Stool-DNA
Con.
1 0.0 0.0 0.0
2 0.0 0.0 0.0
3 0.0 0.0 0.0
4 0.0 0.0
5 0.0 0.0 0.0
6 0.0 0.0 0.0
Median 0.0 0.0 0.0
IV, rAdV mCherry
1 2528.2 33.4 3.7
2 390.3 3.3 0.0
3 1808.4 8.5 1.6
4 217.9 5.1 0.
5 230.4 4.9 0.9
6 26.2 5.5 0.8
7 63.1 4.0 2.6
Median 230.4 a, b 5.1 a, b 0.9 a, b
LM, rAdV mCherry
1 56.2 0.0 1.8
2 11.8 0.0 0.0
3 16.5 0.0 0.0
4 30.7 0.0 0.0
5 15.9 0.0 0.0
6 31.7 0.0 0.0
7 28.3 0.0 0.0
Median 28.3 c 0.0 0.0
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For ddPCR, transgene fragments were detected in all specimens in the IV group, with strong
signals for DNA from the blood cell fraction. However, in the LM group, small amounts of transgene
fragments were observed in the blood cell fraction DNA, and significantly lower amounts were found
in stool DNA; fragments were not detected in plasma cfDNA and stool DNA. Additionally, variations
between individual values were also very large (Figure 4, Table 4).
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3.3. ddPCR on Chronic Experiments Showed a Possibility of Detecting Transgenes Repeatedly
From the results of the acute experiments, a combination method of ddPCR and blood cell fraction
DNA had the highest sensitivity for detecting transgene fragments, and it was hypothesized that
performing ddPCR with whole blood DNA is useful for detecting transgene fragments over several
days. Therefore, we performed the combination method in the chronic experiment. In the results,
transgene fragments could be detected. The transgene fragments mainly existed between one and
three days, especially in the IV group, but decreased sharply after three days. The fragments could be
detected for approximately seven days in the IV group, and for five days in the LM group (Figure 5,
Table 5). Additionally, variations between individual values were very large.
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Table 4. Detection of transgene fragments from droplet digital PCR ddPCR. Transgene fragments were
detected in blood cell fraction DNA in the IV group. IV means intravenous injection, and LM means
local muscular injection of the rAdV vector in the tibialis anterior (TA) muscle. a: p < 0.01 vs. con.
within same specimens. b: p < 0.05 vs. local injection within same specimens. c: p < 0.05 vs. con.
within same specimens. d: p = 0.089 vs. con. within the same specimens.
Group Mouse No.
Copy/µL of Transgene
Blood Cell Fraction-DNA Plasma-cfDNA Stool-DNA
Con.
1 0.0 0.0 0.0
2 0.0 0.0 0.0
3 0.0 0.8 0.7
4 0.0 0.0 0.0
5 0.6 0.0 0.0
6 0.0 0.8 0.0
Median 0.0 0.0 0.0
IV, rAdV mCherry
1 4460.0 19.2 2.3
2 620.7 0.7 2.2
3 2873.3 6.0 5.5
4 276.7 4.3 0.0
5 190.0 2.3 0.0
6 13.7 1.9 0.8
7 42.7 2.5 1.5
Median 276.7 a, b 2.5 a, b 1.5 a
LM, rAdV mCherry
1 34.0 0.0 0.7
2 5.5 0.0 0.0
3 4.5 3.0 0.7
4 12.9 1.4 0.0
5 3.8 0.0 0.7
6 16.5 0.0 1.4
7 11.5 0.0 1.5
Median 11.5 c 0.0 0.7 d
Table 5. Repeated detection of transgene fragments using ddPCR.
Mouse No.
Copy/µL of Transgene
Pre 1 day 3 days 5 days 7 days 9 days 11days
13
days
15
days
IV, rAdV mCherry
1 0.0 817.0 1398.0 48.0 4.3 1.4 0.0 0.8 0.0
2 0.0 890.0 209.0 25.0 2.4 0.0 0.7 3.4 0.7
3 0.8 1108.0 796.0 10.3 0.9 0.0 0.0 10.4 0.0
4 2.0 1422.0 298.0 13.7 1.4 2.7 1.7 0.0 0.0
5 0.7 1900.0 1132.0 62.0 10.5 1.4 1.6 1.5 0.8
6 0.0 4800.0 1261.0 39.0 7.1 2.0 0.7 0.9 1.5
Median 0.4 1265.0 964.0 32.0 3.4 1.4 0.7 1.2 0.4
p- values vs Pre 0.0002 0.0004 0.0063 0.0911 0.4181 0.5886 0.2992 0.6177
LM, rAdV mCherry
1 0.0 70.0 66.0 7.3 0.7 0.8 0.0 0.0 0.0
2 0.9 149.0 24.0 5.0 1.6 0.7 0.0 0.0 0.0
3 0.0 19.0 7.2 4.2 0.7 0.0 0.0 0.0 0.0
4 0.0 10.4 4.6 0.8 0.8 0.7 0.0 0.0 0.0
5 0.0 8.6 9.0 0.0 0.8 0.8 0.0 1.5 0.0
6 0.0 5.2 27.0 4.1 0.0 0.7 0.0 0.0 0.0
Median 0.0 14.7 16.5 4.2 0.8 0.7 0.0 0.0 0.0
p- values vs Pre 0.0012 0.0012 0.0666 0.2576 0.2902 0.5904 0.7753 0.5907
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Transgene fragments could be detected consistently after one and three days post-transfection,
especially in the IV group, but decreased sharply after three days with elapsed time. IV means
intravenous injection, and LM means local muscular injection of the rAdV in tibialis anterior (TA) muscle.
4. Discussion
We tried to develop a detection method for transgenes delivered by rAdV vectors in a gene
delivery mouse model. We successfully detected transgenes containing the mCherry gene in blood
fraction DNA, plasma cfDNA, stool DNA, and whole blood DNA, using sqPCR, qPCR, and ddPCR.
Both IV and LM groups showed gene expression and functional protein expression in liver tissue and
TA muscles. Therefore, our model mimics the gene delivery model for liver or local muscle, which
can potentially be used in gene doping. However, the model is not a true representative of gene
doping, since the aim was not to enhance muscle endurance or power of mice. Nevertheless, this
model resembles gene doping in terms of rAdV vectors, since a functional protein was successfully
expressed in the liver or local muscle tissue. Hence, it is believed that this model can be useful for
developing novel detection methods for transgene fragments in gene doping.
After comparing combinations of three different PCR methods and three different specimens, it
was observed that a combination of ddPCR and blood cell fraction DNA was highly sensitive for the
detection of a transgene. However, this method has the limitation of being invasive. Moreover, we
detected transgene fragments in stool DNA samples as well, although in low amounts. Therefore, there
is the possibility that non-invasive sampling for gene doping could be achieved by using stool DNA.
We observed that transgene fragments predominantly exist in blood fraction. Therefore, it is recommended
to use blood cell fraction for the examination of gene doping by rAdV vectors. Additionally, it is also
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considered that rAdV vectors are captured by neutrophils, monocytes, or macrophages, or are attached
to red blood cells. To solve these questions, further experiments, such as sorting different types of cells
using flow cytometry, are needed.
We hypothesized that the concept of liquid biopsy for the diagnosis or monitoring of cancer—that
is, to analyze specific DNA fragments in cancer cells using plasma cfDNA—would be useful for the
detection of transgene fragments. Therefore, initially in this study, we tried to detect the transgene
fragment using plasma cfDNA in acute experiments, using the concept of liquid biopsy. However, the
number of fragments detected in the plasma cfDNA was much lower than that in blood cell fraction
DNA isolated from IV group. Additionally, no fragment was detected in the LM group. We used
relatively smaller mice in our experiments, and only 240 µL of sample was used to extract cfDNA,
resulting in a low yield of DNA. Therefore, it is likely that if the amount of plasma used to extract
cfDNA is increased, the detection of transgene fragments could be more sensitive.
It has been reported that human candidate genes at a high risk of gene doping include EPO,
insulin-like growth factor-1 (IGF-1), hypoxia inducible factor-1 (HIF-1), vascular endothelial growth
factor-a (VEGF-A), and follistatin (FST), etc. [20–22]. Gene doping may enhance their expression.
Moreover, silencing the gene expression of myostatin by RNA interference (RNAi) technology may
lead to a risk of artificially increased muscle mass [23,24], since animal experiments have shown an
increase in muscle mass using naked plasmid DNA expressed as a small hairpin RNA (shRNA) [23] or
cholesterol-conjugated small interfering RNA (siRNA) [24]. Although there are many target genes
that can be possibly used for gene doping, our PCR methods can detect only one decided transgene.
Therefore, in near future, it is necessary to develop methods that can detect multiple different transgene
fragments and different vectors simultaneously. In order to achieve this, a comprehensive analysis by
next-generation sequencing (NGS) technology may be necessary.
Surprisingly, in ddPCR experiments, positive droplets were detected in DNA samples of
rAdV-negative samples, although mice of the injected group and control group were completely
separated. Additionally, ddPCR is believed to be highly precise and sensitive for the quantification
of absolute values, according to Bio-Rad Laboratories, Inc. Therefore, there is a possibility of
cross-contamination by transgenes of positive samples. Such cross-contamination must be absolutely
avoided during the examination of gene doping. Therefore, we have the challenge to apply robot
technology that resembles human moves for examination of gene doping. The robot named “Maholo”,
developed by LabDroid (Robotic Biology Institute), demonstrates the concept that humanoid robots in
laboratory can solve problems, such as numerous labor-intensive tasks required in high-throughput
research, as well as the dangers (and costs) associated with experiments involving pathogens and
harmful reagents [25]. Maholo can perform various tasks, including automating sample preparations
in a clean room with a low risk of artificial contaminations. Currently, we have tested and established
practicality and developed a computer system to apply testing for the detection of transgene fragments
in our model mice by Maholo. This technology might be used in human applications in future.
5. Conclusions
In the present study, transgene fragments could directly be detected from blood cell fraction
DNA, plasma cfDNA, and stool DNA by qPCR and ddPCR methods in a gene delivery mice model,
depending on specimen type and injection methods. Additionally, it was observed that a combination
of blood cell fraction DNA and ddPCR is more sensitive than other combinations used in this model.
These results could accelerate the establishment of examination methods for gene doping.
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